January 05, 2017 09:00 ET

AXIM Biotech Advances IBS Program After Successful Dosing Study --

REDONDO BEACH, CA--(Marketwired - Jan 5, 2017) -, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing the recent, successful completion of AXIM® Biotechnologies' (OTCQB: AXIM) pharmacokinetic (PK) study of its CanChew Plus® CBD Gum. The single-dose study on 10 mg and 30 mg concentrations of cannabidiol (CBD) measured blood concentrations after chewing a single piece of gum for 30 minutes. The 30 mg dosage showed excellent bioavailability and will be used in the upcoming AX-1601 clinical trial.

The company will use the dosing data to determine the most optimal dosing for patients involved in its clinical trial, which will evaluate the safety and efficacy of CBD in treating the symptoms of Irritable Bowel Syndrome (IBS). In pre-clinical studies, CBD has been shown to modulate inflammation by interacting at extra-cannabinoid system receptor sites, such as peroxisome proliferator-activated receptor-gamma and other important targets.

According to Global Data, a research and consulting firm, the global therapeutics market for IBS is set to grow at a 9.9% annual rate from $589.6 million in 2013 to $1.5 billion by 2023. Allergan plc's Linzess is expected to contribute the highest revenue at $307.2 million by 2023, as a second-line treatment in patients suffering from constipation-predominant IBS (IBS-C), although there's growing competition from companies like Abbott Laboratories. AXIM® Biotech appears to be the only company pursuing clinical trials that evaluate CBD for the treatment of IBS.

Please follow the link to read the full article:


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information